2-(6-溴-1H-吲哚-3-基)乙胺盐酸盐 | 108061-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-(6-溴-1H-吲哚-3-基)乙胺盐酸盐
• 中文别名: 6-溴-1H-吲哚-3-乙胺盐酸盐；2-(6-溴吲哚-3)-乙胺盐酸盐
• 英文名称: 6-bromotryptamine hydrochloride
• 英文别名: 2-(6-Bromo-1H-indol-3-YL)ethanamine hydrochloride；2-(6-bromo-1H-indol-3-yl)ethanamine;hydrochloride
• CAS: 108061-77-4
• 化学式: C₁₀H₁₁BrN₂*ClH
• 分子量: 275.576
• InChiKey: KFXZBTZAVZBFET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.28
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.4
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(6-溴-1H-吲哚-3-基)乙胺盐酸盐 在 盐酸 、 氢氧化钾 作用下， 以 水 为溶剂， 反应 1.75h， 生成 7-溴-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚
  参考文献：
  名称：

  Eudistomins A-Q, .beta.-carbolines from the antiviral Caribbean tunicate Eudistoma olivaceum

  摘要：

  DOI：

  10.1021/ja00245a031
• 作为产物：
  描述：

  2-乙酰氨基-1,2,5-三脱氧-1,5-亚氨基-d-葡萄糖醇 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 2-(6-溴-1H-吲哚-3-基)乙胺盐酸盐
  参考文献：
  名称：

  溴化海洋生物碱（±）-阿糖胞苷A，B和C的合成

  摘要：

  描述了从6-溴-（N-甲基）色胺的直接合成溴化海洋生物碱阿糖胞苷A（1），B（2）和C（3）的方法。的平衡，碱性和酸性条件下被发现之间存在反式-和顺式-异构体3和4。光谱数据表明，异构体4的结构与最近从海洋被膜植物假单胞菌假单胞菌中分离出的鉴定为阿糖胞苷D的化合物不符。

  DOI：

  10.1016/s0040-4020(98)00306-8

文献信息

• Tandem iodine-mediated oxidations of tetrahydro-β-carbolines: total synthesis of eudistomins Y1–Y7
  作者：Joseph D. Panarese、Stephen P. Waters

  DOI：10.1039/c3ob40661j

  日期：——

  An efficient iodine-mediated oxidation of tetrahydro-β-carbolines is described to yield aromatic β-carboline products with tandem C–H oxidation. The utility of the method was demonstrated in total syntheses of the alkaloids eudistomins Y1–Y7.

  报道了一种高效的碘介导的四氢-β-咔啉氧化反应，通过串联C-H氧化生成芳香β-咔啉类产物。该方法在生物碱合成中得到了应用，证明了其在尤迪斯通明素Y1至Y7的全合成中的实用性。
• METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
  申请人：Almstead Neil

  公开号：US20120202763A1

  公开（公告）日：2012-08-09

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.

  本文介绍了选择性抑制人类血管内皮生长因子（VEGF）病理性产生的化合物以及包含这些化合物的组合物。本文还介绍了抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的化合物以及包含这些化合物的组合物。同时，本文还介绍了使用这些化合物减少VEGF的方法以及使用这些化合物治疗癌症和非肿瘤性疾病的方法。本文还介绍了使用这些化合物抑制病毒复制或病毒RNA或DNA或病毒蛋白质产生的方法以及使用这些化合物治疗病毒感染的方法。这些化合物可以作为单一治疗剂或与一个或多个其他治疗剂联合使用，用于治疗需要这些治疗的人类。
• METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION
  申请人：PTC Therapeutics, Inc.

  公开号：US20200317668A1

  公开（公告）日：2020-10-08

  Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of inhibiting or reducing viral replication or the production of viral RNA or DNA or viral protein using such Compounds, and methods for treating viral infections, such as an RNA virus belonging to the family Coronaviridae, involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.
• US9351964B2
  申请人：——

  公开号：US9351964B2

  公开（公告）日：2016-05-31
• [EN] METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'UN CANCER ET D'ÉTATS NON NÉOPLASIQUES
  申请人：PTC THERAPEUTICS INC

  公开号：WO2010138758A1

  公开（公告）日：2010-12-02

  Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments.